이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Real-world Evidence With Long-Acting User-optimized Growth Hormone Therapy in Pediatric Growth Hormone Deficiency (REAL-LAUGH)

2026년 11월 10일 업데이트: Fundació Sant Joan de Déu

The REAL-LAUGH study will compare changes in body composition and other health outcomes in children and adolescents with growth hormone deficiency who start weekly or daily growth hormone treatment in routine clinical practice in Spain.

Approximately 110 participants aged 3 to 16 years will be enrolled: 55 receiving weekly long-acting growth hormone and 55 receiving daily recombinant human growth hormone. The treating physician will select treatment as part of usual care, independently of study participation. The study will not assign treatment.

Participants will be followed for 12 months, with assessments at baseline, 6 months, and 12 months. The main outcome is the change in percentage total body fat measured by dual-energy X-ray absorptiometry, also called DXA, between baseline and 12 months. The study will assess whether the reduction in body fat with weekly treatment differs from that with daily treatment.

Other assessments will include lean body mass, growth, waist measurements, blood pressure, glucose and lipid metabolism, carotid artery wall thickness, bone mineral density, pubertal development, bone age, IGF-1 concentrations, and adverse events. No biological samples will be stored for research.

연구 개요

연구 유형

관찰

등록 (추정된)

110

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Marta Ramon Krauel, MD PhD
  • 전화번호: 71702 +34 932 804 000
  • 이메일: marta.ramon@sjd.es

연구 장소

      • Santiago de Compostela, 스페인
        • Hospital Clínico Universitario de Santiago
        • 연락하다:
    • Barcelona
      • Barcelona, Barcelona, 스페인, 08950
        • Hospital Sant Joan de Déu
        • 연락하다:
          • Marta Ramon Krauel, MD PhD
          • 전화번호: 71702 +34 932 804 000
          • 이메일: marta.ramon@sjd.es
    • Madrid
      • Madrid, Madrid, 스페인
    • Valencia
      • Valencia, Valencia, 스페인
        • Hospital Universitario y Politécnico La Fe
        • 연락하다:
    • Zaragoza
      • Zaragoza, Zaragoza, 스페인
        • Hospital Universitario Miguel Servet
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

3년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Children and adolescents aged 3 to 16 years with growth hormone deficiency who attend participating pediatric endocrinology departments in Spain and are initiating either weekly long-acting growth hormone or daily recombinant human growth hormone in routine clinical practice. Eligible candidates will be identified during routine clinical visits and invited to participate.

설명

Inclusion Criteria:

  • Age between 3 and 16 years.
  • Diagnosis of growth hormone deficiency according to standard clinical practice in Spain and the applicable Spanish Ministry of Health criteria.
  • Growth hormone treatment approved by the relevant local authorities and institution.
  • Initiation of treatment with long-acting growth hormone or daily recombinant human growth hormone.

Exclusion Criteria:

- Recombinant human growth hormone prescribed for an indication other than growth hormone deficiency.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Weekly Long-Acting Growth Hormone

Children and adolescents with growth hormone deficiency initiating once-weekly somatrogon as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

LAGH administered by subcutaneous injection once weekly as part of routine clinical care. Prescribed doses and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

다른 이름들:
  • 소마트로곤
  • NGENLA
Daily Recombinant Human Growth Hormone

Children and adolescents with growth hormone deficiency initiating daily somatropin as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

Human recombinant growth hormone administered by daily subcutaneous injection as part of routine clinical care. Prescribed products, doses, and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

다른 이름들:
  • 소마트로핀
  • 노르디트로핀
  • 옴니트로프
  • 유전자형

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Percentage Total Body Fat
기간: Baseline and 12 months

Change in percentage total body fat measured by dual-energy X-ray absorptiometry (DXA), calculated as the 12-month value minus the baseline value and expressed in percentage points. Percentage total body fat is calculated as total fat mass divided by total body mass, multiplied by 100. Negative changes indicate a reduction in percentage total body fat. The adjusted between-cohort difference in change, defined as long-acting growth hormone minus daily recombinant human growth hormone, will be evaluated.

Baseline and 12 months

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Lean Body Mass
기간: Baseline and 12 months

Change in lean body mass measured by DXA, calculated as the 12-month value minus the baseline value and expressed in kilograms.

Baseline and 12 months
Change in body mass index standard deviation score (BMI-SDS)
기간: Baseline and 12 months

Change in age- and sex-standardized BMI-SDS from baseline to 12 months. Weight and height will be used to calculate BMI-SDS based on World Health Organization tables.

Baseline and 12 months
Change in height standard deviation score (SDS)
기간: Baseline and 12 months

Change in height SDS from baseline to 12 months. Height will be used to calculate BMI-SDS based on World Health Organization tables.

Baseline and 12 months
Change in Waist Circumference
기간: Baseline and 12 months

Change in waist circumference from baseline to 12 months, expressed in centimeters.

Baseline and 12 months
Change in Waist-to-Hip Ratio
기간: Baseline and 12 months

Change in waist circumference divided by hip circumference from baseline to 12 months. The ratio is dimensionless.

Baseline and 12 months
Change in Systolic Blood Pressure
기간: Baseline and 12 months

Change in systolic blood pressure from baseline to 12 months, expressed in mmHg.

Baseline and 12 months
Change in Diastolic Blood Pressure
기간: Baseline and 12 months

Change in diastolic blood pressure from baseline to 12 months, expressed in mmHg.

Baseline and 12 months
Change in Fasting Glucose Concentration
기간: Baseline and 12 months

Change in fasting blood glucose concentration from baseline to 12 months.

Baseline and 12 months
Change in Fasting Insulin Concentration
기간: Baseline and 12 months

Change in fasting blood insulin concentration from baseline to 12 months.

Baseline and 12 months
Change in HOMA-IR
기간: Baseline and 12 months

Change in the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and insulin concentrations, from baseline to 12 months.

Baseline and 12 months
Change in Total Cholesterol Concentration
기간: Baseline and 12 months

Change in total cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in LDL Cholesterol Concentration
기간: Baseline and 12 months

Change in LDL cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in HDL Cholesterol Concentration
기간: Baseline and 12 months

Change in HDL cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in Triglyceride Concentration
기간: Baseline and 12 months

Change in Triglyceride concentration from baseline to 12 months.

Baseline and 12 months
Change in Change in Carotid Intima-Media Thickness
기간: Baseline and 12 months

Change in carotid intima-media thickness measured bilaterally by high-resolution ultrasound at baseline and 12 months, expressed in millimeters.

Baseline and 12 months
Change in Bone Mineral Density Z-Score
기간: Baseline and 12 months

Change in bone mineral density Z-score measured by DXA from baseline to 12 months.

Baseline and 12 months
Change in Height Standard Deviation Score
기간: Baseline and 12 months

Change in height standard deviation score (height SDS) from baseline to 12 months.

Baseline and 12 months
Change in Growth Velocity Standard Deviation Score
기간: Baseline and 12 months

Change in growth velocity standard deviation score from baseline to 12 months.

Baseline and 12 months
Change in Bone Age Minus Chronological Age
기간: Baseline and 12 months

Change in the difference between bone age and chronological age from baseline to 12 months, expressed in years. Bone age will be assessed by manual reading using the Greulich and Pyle atlas.

Baseline and 12 months
Change in IGF-1 standard deviation score
기간: Baseline and 12 months

Change in insulin-like growth factor 1 (IGF-1) standard deviation score from baseline to 12 months.

Baseline and 12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2028년 6월 1일

연구 완료 (추정된)

2028년 6월 1일

연구 등록 날짜

최초 제출

2026년 11월 10일

QC 기준을 충족하는 최초 제출

2026년 11월 10일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data sharing with external researchers is not planned under the current protocol. Any future third-party data communication would require prior institutional assessment and authorization. The protocol limits such communication to aggregated data from which participants cannot reasonably be identified.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다